Thursday, 19 October 2017
Latest news
Main » Gilead Sciences, Inc. (NASDAQ:GILD) showed P/E ratio

Gilead Sciences, Inc. (NASDAQ:GILD) showed P/E ratio

13 October 2017

About 3.60M shares traded. It has underperformed by 16.99% the S&P500.

Ltd says it lowered its investment in Gilead Sciences, Inc. shares by 300 shares in its quarterly SEC filing. Schnieders Capital Management Llc acquired 5,275 shares as Merck & Co Inc (MRK)'s stock declined 2.46%. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company's stock worth $617,000 after buying an additional 26 shares during the last quarter. Gilead Sciences Inc now has $105.95B valuation. Days to cover decreased 0.0 to 2.0 and the percentage of shorted shares is 0.02% as of September 15. About shares traded. Old Line Bancshares, Inc.

Gilead Sciences, Inc. (GILD) now the company's industry has 13.86 P/E and the sector P/E is 16.24. It has underperformed by 38.50% the S&P500.

Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on November, 8. They expect $2.34 earnings per share, up 20.62% or $0.40 from last year's $1.94 per share. GILD's profit will be $2.70 billion for 9.86 P/E if the $2.07 EPS becomes a reality. Arrow Financial Corp lifted its holdings in shares of Gilead Sciences by 0.3% during the 2nd quarter. 557.32 million shares or 1.16% less from 563.88 million shares in 2017Q1 were reported. Deere & Co (NYSE:DE) was reduced too.

Among 19 analysts covering Bill Barrett Corporation (NYSE:BBG), 4 have Buy rating, 2 Sell and 13 Hold.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. Standpoint Research initiated Gilead Sciences, Inc. The company was maintained on Wednesday, January 6 by Barclays Capital. Twelve analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the stock. On Wednesday, August 19 the stock rating was maintained by BTIG Research with "Buy". Zacks downgraded CIGNA Corporation (NYSE:CI) on Wednesday, August 5 to "Buy" rating. The firm has "Buy" rating by J.P. Morgan given on Monday, July 24. The company was maintained on Wednesday, May 31 by Mizuho. The firm has "Neutral" rating by Bank of America given on Wednesday, October 4. (NASDAQ:GILD) earned "Hold" rating by BMO Capital Markets on Friday, July 21. On Tuesday, November 8 the stock rating was upgraded by Oppenheimer to "Outperform".

Investors sentiment decreased to 0.91 in 2017 Q2. Its the same as in 2017Q1. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company's stock worth $211,000 after buying an additional 11 shares during the last quarter. Global Thematic Prns Ltd Liability Corporation invested in 1.05M shares or 2.38% of the stock. Eqis Cap Inc stated it has 0.01% in Mylan N.V. (NASDAQ:MYL). Gulf Int National Bank & Trust (Uk) Limited invested 0.08% of its portfolio in Mylan N.V. (NASDAQ:MYL). It also upped Ishares Core S&P Small Cap Etf (IJR) stake by 7,235 shares and now owns 70,157 shares. Therefore 21% are positive. Jefferies Group LLC reiterated a hold rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 11th. $341,529 worth of Gilead Sciences, Inc. The firm earned "Mkt Perform" rating on Tuesday, September 27 by Leerink Swann. The firm earned "Outperform" rating on Wednesday, February 3 by RBC Capital Markets. The rating was upgraded by Argus Research on Thursday, August 31 to "Buy". October 6 investment analysts at Morgan Stanley left the company rating at "Equal-Weight" and lowered the price expectation to $83.00 from $103.00. (NASDAQ:GILD). 12,320 are held by Ledyard Bancorporation. The company was maintained on Friday, April 29 by UBS. The company was maintained on Wednesday, March 23 by Credit Suisse. 5,000 Gilead Sciences, Inc. (MD) (NASDAQ:OLBK) earned "Outperform" rating by Keefe Bruyette & Woods on Tuesday, November 29. After $0.38 actual EPS reported by U.S. Silica Holdings Inc for the previous quarter, Wall Street now forecasts 23.68% EPS growth.

Since May 1, 2017, it had 0 buys, and 5 insider sales for $11.13 million activity. 9,943 shares were sold by Cogan John Francis, worth $668,667. 73,333 shares valued at $4.78M were sold by MARTIN JOHN C on Thursday, June 1.

Investors sentiment decreased to 0.5 in 2017 Q2. 217.98 million shares or 0.25% less from 218.52 million shares in 2017Q1 were reported. It is positive, as 78 investors sold GILD shares while 538 reduced holdings. 0 funds opened positions while 3 raised stakes. Paradigm Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 0.3% in the second quarter. Monetary Mngmt Gp has 0.79% invested in Gilead Sciences, Inc. Moreover, Crestwood Advsr Group Inc Ltd Liability Com has 0.07% invested in Merck & Co., Inc. Smith Chas P & Associate Pa Cpas reported 2.94% of its portfolio in Merck & Co., Inc. (GILD). These ratios are important while doing valuation of the company or the shares of the company. (MD) (NASDAQ:OLBK). 24,429 were accumulated by Menta Ltd Limited Liability Company. Oakwood Management Lc Ca has invested 0.88% in Gilead Sciences, Inc. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company's stock worth $632,000 after acquiring an additional 39 shares during the last quarter. Dana stated it has 28,059 shares. Twin Tree Management LP reported 81,575 shares. Clean Yield Gru stated it has 51,833 shares. Sei Investments accumulated 0.16% or 242,683 shares. Investec Asset Mngmt Limited owns 94,307 shares or 0.03% of their United States portfolio. Hussman Strategic Advsrs holds 0.39% in Gilead Sciences, Inc. Perhaps, that suggests something about why 75.16% of the outstanding share supply is held by institutional investors. Alabama-based Weiss Multi has invested 0.13% in Centurylink Inc (NYSE:CTL).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Gilead Sciences, Inc. (NASDAQ:GILD) showed P/E ratio